Service Optimisation of Prostate Cancer Therapy Pathway

This document is a report detailing the outputs from a collaborative working project between Astellas Pharma Ltd and Royal Surrey NHS Foundation Trust focused on optimizing the Prostate Cancer Oral Systemic Anti-Cancer Therapy (SACT) pathway. The project aims to enhance the efficiency of the cancer service by identifying and addressing inefficiencies, delays, and bottlenecks within the existing pathway. The report highlights the significant burden of new prostate cancer cases on NHS resources, with 55,300 patients diagnosed annually. It outlines various identified issues affecting clinic flow, including staffing challenges, inconsistent follow-up intervals, and procedural delays. Additionally, it presents successful aspects of the pathway, such as established protocols and multidisciplinary support services. The document concludes with proposed solutions to improve patient management and clinic capacity, including the development of an electronic patient-reported outcome measures toolkit and the establishment of nurse-led clinics for new patients.